Skip to main content

Table 3 Weaning Schedule for Study Sildenafil or Placebo in Cohorts 2 and 3

From: Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study

Weaning Days

IV

Enteral

1–2

75% of last study dose

75% of last study dose

3–4

50% of last study dose

50% of last study dose

5–6

25% of last study dose

25% of last study dose

7

Discontinue

Discontinue

  1. Abbreviation: IV intravenous